Angiotensin inhibition via ACE inhibitors or angiotensin receptor blockade provides beneficial hemodynamic effects in hypertension, ischemic heart disease, and heart failure.
This historical review outlines the foundational research that led to the widespread use of ACE inhibitors and ARBs in treating hypertension, ischemic heart disease, and heart failure.
This is a personal historical account relating the events that led to the first application of angiotensin inhibition (either by ACE inhibitors or by angiotensin receptor blockade) to the investigation of the pathogenesis and treatment of hypertension, ischemic heart disease, and heart failure. Included are animal experiments, clinical observations, and the earliest clinical experimental studies that helped define some of the detrimental effects of angiotensin II and the beneficial hemodynamic results of its inhibition, which have been subsequently corroborated and amplified by large randomized outcome trials.
Gavras et al. (Thu,) conducted a review in Hypertension, Ischemic Heart Disease, and Heart Failure. Angiotensin inhibition (ACE inhibitors or angiotensin receptor blockade) was evaluated. Angiotensin inhibition via ACE inhibitors or angiotensin receptor blockade provides beneficial hemodynamic effects in hypertension, ischemic heart disease, and heart failure.